These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16336728)

  • 1. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
    Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB
    Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R; Roychoudhury J; Palit P; Ali N
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.
    Carter KC; Hutchison S; Henriquez FL; Légaré D; Ouellette M; Roberts CW; Mullen AB
    Antimicrob Agents Chemother; 2006 Jan; 50(1):88-95. PubMed ID: 16377672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R; Mullen AB; Carter KC
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells.
    Mukhopadhyay R; Mukherjee S; Mukherjee B; Naskar K; Mondal D; Decuypere S; Ostyn B; Prajapati VK; Sundar S; Dujardin JC; Roy S
    Int J Parasitol; 2011 Nov; 41(13-14):1311-21. PubMed ID: 21920365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
    Carter KC; Sundar S; Spickett C; Pereira OC; Mullen AB
    Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A; Singh N; Sundar S; Singh N
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani.
    Samant M; Sahasrabuddhe AA; Singh N; Gupta SK; Sundar S; Dube A
    Parasitology; 2007 Aug; 134(Pt 9):1175-84. PubMed ID: 17362540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
    Roychoudhury J; Sinha R; Ali N
    PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
    Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
    J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J; Kaur S
    Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
    Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
    J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the benzodiazepines as a new class of antileishmanial agent.
    Clark RL; Carter KC; Mullen AB; Coxon GD; Owusu-Dapaah G; McFarlane E; Duong Thi MD; Grant MH; Tettey JN; Mackay SP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):624-7. PubMed ID: 17113290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
    Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC; Baillie AJ; Mullen AB
    Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.